Table 3.
Absolute number and percentage reduction of total lesions and non‐inflammatory lesions (FAS)
| Cohorts | Baseline, no. of lesions | End of study, no. of lesions | Absolute reduction, no. lesions | Percentage reduction, % |
|---|---|---|---|---|
| No. of TL | ||||
| 2.5% BPO gel (203 cases) | 50 (40–63) | 21 (10–35) | 29*** (17 to 38) | 62.2*** (33.3 to 79.6) |
| Difference from placebo | – | −16 | 16 (12 to 20) | 29.4 (22.7 to 36.5) |
| 5% BPO gel (203 cases) | 51 (40–64) | 18 (8–30) | 31*** (23 to 43) | 67.9*** (48.6 to 81.8) |
| Difference from placebo | – | −18 | 20 (16 to 24) | 36.0 (29.3 to 42.9) |
| Placebo | 51 (41–67) | 36 (22–59) | 14 (−2 to 28) | 28.6 (−3.9 to 54.4) |
| No. of non‐IL | ||||
| 2.5% BPO gel (203 cases) | 29 (23–40) | 14 (7–25) | 16*** (7 to 24) | 56.5*** (26.3 to 78.3) |
| Difference from placebo | – | −10 | 10 (7 to 13) | 29.5 (21.4 to 37.6) |
| 5% BPO gel (203 cases) | 30 (23–41) | 11 (6–21) | 19*** (12 to 26) | 68.2*** (38.7 to 81.4) |
| Difference from placebo | – | −12 | 13 (10 to 16) | 37.5 (29.7 to 45.2) |
| Placebo | 30 (23–43) | 25 (14–41) | 7 (−4 to 17) | 21.9 (−13.0 to 53.3) |
***Median (interquartile range). Difference from placebo: Hodges–Lehmann estimator (95% confidence intervals). P < 0.001 vs placebo (Wilcoxon two sample test). Difference from placebo: Hodges‐Lehmann estimator (95% confidence intervals). P < 0.001 vs placebo (Wilcoxon two sample test). BPO, benzoyl peroxide; FAS, full analysis set; IL, inflammatory lesions; SD, standard deviation; TL, total lesions.